Pier Luigi Zinzani
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola(IT)Policlinico S.Orsola-Malpighi(IT)Istituto di Ematologia di Bologna(IT)Azienda USL di Bologna(IT)Istituto delle Scienze Neurologiche di Bologna(IT)Istituto Oncologico Romagnolo(IT)Istituti di Ricovero e Cura a Carattere Scientifico(IT)University of Bologna(IT)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, Viral-associated cancers and disorders, Cutaneous lymphoproliferative disorders research
Most-Cited Works
- → CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group(2006)2,073 cited
- → Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial(2010)1,860 cited
- → Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.(2011)1,622 cited
- → The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee(2022)1,387 cited
- → PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma(2014)1,053 cited
- → Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma